A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

Organon and Co135 enrolled

Overview

The study will assess the safety and tolerability of Ezetimibe 10 mg+ Rosuvastatin 2.5 mg and Ezetimibe 10 mg+ Rosuvastatin 5.0 mg for up to 52 weeks in Japanese participants with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10 mg or Rosuvastatin up to 5 mg.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

135

Conditions

Hypercholesterolemia Familial Hypercholesterolemia

Interventions

EzetimibeDRUG

RosuvastatinDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Japanese * Outpatient with hypercholesterolemia * Female participant who is of reproductive potential has to agree to remain abstinent or use (or partner use) two acceptable methods of birth control from date of signed informed consent to the 14 days after the last dose of study drug * Will maintain a stable diet that is consistent with the Japan Atherosclerosis Society Guideline 2012 (JAS 2012) for prevention of atherosclerotic cardiovascular diseases for the duration of the study Exclusion Criteria: * Uncontrolled hypertension (treated or untreated) * Uncontrolled type 1 or type 2 diabetes mellitus * Homozygous Familial Hypercholesterolemia or has undergone low-density lipoprotein (LDL) apheresis * Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins * Has had a gastrointestinal tract bypass, or other significant intestinal malabsorption * History of cancer within the past 5 years (except for successfully treated dermatological basal cell or squamous cell carcinoma or in situ cervical cancer) * Human Immunodeficiency Virus (HIV) positive * History of drug/alcohol abuse within the past 5 years or psychiatric illness not adequately controlled and stable on pharmacotherapy * Consumes more than 25 g of alcohol per day * Currently following an excessive weight reduction diet * Currently engages in a vigorous exercise regimen (e.g.; marathon training, body building training etc.) or intends to start training during the study * Hypersensitivity or intolerance to Ezetimibe or Rosuvastatin * Myopathy or rhabdomyolysis with Ezetimibe or any statin * Pregnant or lactating * Taking any other investigational drugs and/or has taken any investigational drugs within 30 days

Outcomes

Primary Outcomes

Percentage of Participants Who Experience at Least 1 Adverse Event (AE)

An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who reported at least 1 AE was summarized.

Time frame: Up to 2 weeks post last dose of study drug (up to 54 weeks)

Percentage of Participants Who Had Study Drug Discontinued Due to an AE

Time frame: up to 52 weeks

Secondary Outcomes

Percentage Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Blood was collected at baseline (predose) and after 52 weeks of treatment to determine LDL-C levels. LDL-C was calculated using the Friedewald equation. If triglycerides (TG) exceeded 400 mg/dL (4.6 mmol/L), LDL-C was determined by beta quantification ultracentrifugation. The percentage change from baseline at Week 52 was summarized.

Time frame: Baseline (predose) and Week 52

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.